Related Experiment Video
Updated: Aug 13, 2026
07:10
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Relationship between body surface area and ALT normalization after long-term lamivudine treatment
Makoto Nakamuta1, Shusuke Morizono, Yuichi Tanabe
1Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-5282, Japan. nakamuta@intmed3.med.kyushu-u.ac.jp
World Journal of Gastroenterology
|January 27, 2006
Summary
Body surface area (BSA) predicts lamivudine
Area of Science:
- Hepatology
- Pharmacology
- Virology
Background:
- Chronic hepatitis B management requires effective antiviral therapies.
- Lamivudine is a nucleoside analog used to treat chronic hepatitis B.
- Individual patient factors may influence treatment response.
Purpose of the Study:
- To investigate the relationship between body surface area (BSA) and the efficacy of lamivudine treatment in chronic hepatitis B patients.
- To determine if BSA is a predictor of treatment response over extended periods.
Main Methods:
- A cohort of 249 chronic hepatitis B patients receiving lamivudine was evaluated.
- Treatment effects were assessed over one, two, and three years by monitoring serum ALT and HBV-DNA levels.
- Multivariate analysis was used to identify factors influencing biological and virological responses.
Main Results:
- For 1-year and 2-year treatments, BSA was a significant predictor of the biological effect (ALT normalization).
- ALT, HBV-DNA, and HBeAg were independent factors for virological response (undetectable HBV-DNA) in the first year.
- After 3 years, BSA was no longer a significant predictor for ALT normalization.
Conclusions:
- Body surface area (BSA) is a significant predictor for normalizing alanine aminotransferase (ALT) levels during the initial two years of lamivudine therapy.
- These findings suggest that lamivudine dosage adjustments based on individual BSA may optimize treatment outcomes.
- Further research may explore BSA-guided dosing strategies for lamivudine in chronic hepatitis B.
Related Concept Videos
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...